Prescription Drug Benefit Information Transparency
Impact
If enacted, HB 1012 would amend existing state laws to impose stricter regulations on the practices of PBMs and healthcare consultants, categorizing any violations of the disclosure or misinformation provisions as unfair methods of competition and deceptive practices within the insurance domain. Violators could face escalating penalties that include the potential loss of their registration to administer prescription drug benefits. Most importantly, the bill intends to reduce costs for employers and address the escalating prices associated with prescription medications by fostering competition and transparency in drug sourcing practices.
Summary
House Bill 1012, known as the Prescription Drug Sourcing Transparency and Integrity Act, has been introduced to enhance the integrity and transparency surrounding prescription drug sourcing programs administered by pharmacy benefit managers (PBMs) and healthcare consultants. The bill explicitly prohibits PBMs and healthcare consultants from making misleading statements to employers and other stakeholders regarding the legality and safety of alternative prescription drug sourcing options. Additionally, it mandates that upon written request, they must disclose detailed cost information related to each prescription drug dispensed under health benefit plans, aiming to facilitate better pricing transparency for self-funded employers and health benefit sponsors.
Contention
Debates surrounding the bill may arise regarding the balance between regulation and the autonomy of healthcare providers. Proponents argue that the bill protects employers and ensures patients have reliable access to essential medications without the influence of misleading information from PBMs. However, critics could raise concerns about the regulatory burdens placed on these entities, questioning whether the restrictions may inadvertently limit access to certain prescription drugs or impede the clinical decision-making process, as the bill emphasizes transparency and cost control over traditional methods.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.